Lista completa de Publicações

@article{Caleffi2026,

title = {Determination of a new gastric cancer mortality predictor based on body composition radiodensity variables},

author = {Mariana Caleffi and Daniela Morais de Holanda Padilha and Vinicius Bassete and Gianni Liveraro and Pedro Henrique Alves and Maria Emilia Seren Takahashi and Leo Victor Kim and Maria Carolina Santos Mendes and Jun Takahashi and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2026.103132},

issn = {2405-4577},

year  = {2026},

date = {2026-06-00},

urldate = {2026-06-00},

journal = {Clinical Nutrition ESPEN},

volume = {73},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2026,

title = {Diagnostic brain-to-liver [18f]fdg uptake ratio predicts survival in multiple myeloma: A retrospective study},

author = {Maria Emilia S. Takahashi and Tiago P. dos Santos and Christopher Cralcev and Eliana Miranda and Marcos Paulo D. S. Silva and Felipe C. Souza and José Barreto C. Carvalheira and Carmino A. de Souza and Celso Dario Ramos},

doi = {10.1007/s00259-026-07844-z},

issn = {1619-7089},

year  = {2026},

date = {2026-03-21},

urldate = {2026-03-21},

journal = {Eur J Nucl Med Mol Imaging},

publisher = {Springer Science and Business Media LLC},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:sec>

                    <jats:title>Purpose</jats:title>

                    <jats:p>[¹⁸F]FDG PET/CT has been widely used in oncology for diagnosis and treatment monitoring. Reduced cerebral [¹⁸F]FDG uptake has been observed in patients with disseminated malignancies, potentially associated with the Warburg effect and elevated lactate levels. This study investigated the prognostic relevance of the brain-to-liver [¹⁸F]FDG uptake ratio (BLR) in MM patients who underwent PET/CT at diagnosis.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Methods</jats:title>

                    <jats:p>BLR was calculated as the ratio between the mean standardized uptake value (SUV) of the whole brain and that of the liver. A total of 72 patients were retrospectively included in the study (58% male; median age 65 years (IQR55;70); 67% were classified as ISS stage III).</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Results</jats:title>

                    <jats:p>

                      BLR, as a continuous variable, showed a statistically significant difference between groups according to sex (

                      <jats:italic>p</jats:italic>

                       = 0.004), overweight status (

                      <jats:italic>p</jats:italic>

                       = 0.005), and ISS stage (

                      <jats:italic>p</jats:italic>

                       = 0.03), and was negatively correlated with β₂-microglobulin (

                      <jats:italic>r</jats:italic>

                      = − 0.42,

                      <jats:italic>p</jats:italic>

                       < 0.001). With a median follow-up of 23 months (IQR 8; 65), 74% patients had died from MM-related causes. Patients with BLR > 2.7 demonstrated superior 60-month overall survival (52%vs.10%,

                      <jats:italic>p</jats:italic>

                       = 0.002) and progression-free survival (19%vs.3%,

                      <jats:italic>p</jats:italic>

                       = 0.003), respectively. Multivariate Cox regression confirmed BLR (HR 1.86 95%CI: 1.03–3.33,

                      <jats:italic>p</jats:italic>

                       = 0.038 (OS); HR 1.93 95%CI: 1.13–3.29,

                      <jats:italic>p</jats:italic>

                       = 0.016 (PFS))as an independent factor and the use of autologous hematopoietic cell transplantation (HCT) as consolidation for both OS and PFS. In addition, ISS stage III was also a prognostic factor for OS.

                    </jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Conclusion</jats:title>

                    <jats:p>Higher brain-to-liver [¹⁸F]FDG uptake ratio (> 2.7) at diagnosis predicts better clinical outcomes in multiple myeloma. BLR is significantly associated with established clinical markers of tumor burden in multiple myeloma. These findings suggest that BLR is a feasible and reproducible metric with potential prognostic value in multiple myeloma.</jats:p>

                  </jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Antoniolli2026,

title = {In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia},

author = {Giorgio Antoniolli and Gilberto Carlos Franchi Junior and Keli Lima and Rayssa de Mello Lopes and Euzebio Guimarães Barbosa and João Agostinho Machado-Neto and Carmen Silvia Passos Lima and Tiago Rodrigues and Fernando Coelho},

doi = {10.1016/j.taap.2025.117667},

issn = {0041-008X},

year  = {2026},

date = {2026-02-00},

urldate = {2026-02-00},

journal = {Toxicology and Applied Pharmacology},

volume = {507},

publisher = {Elsevier BV},

keywords = {Área Pré-Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Azevedo2026,

title = {Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy},

author = {Fernanda van Petten Vasconcelos Azevedo and Ana Lúcia Tasca Gois Ruiz and Diego Samuel Rodrigues and Douglas Hideki Nakahata and Raphael Enoque Ferraz de Paiva and Daniele Ribeiro de Araujo and Ana Carola de La Via and Wendel Andrade Alves and Michelle Barreto Requena and Cristina Kurachi and Mirian Denise Stringasci and José Dirceu Vollet-Filho and Wilton Rogério Lustri and Vanderlei Salvador Bagnato and Camilla Abbehausen and Pedro Paulo Corbi and Carmen Silvia Passos Lima},

doi = {10.3390/pharmaceutics18020145},

issn = {1999-4923},

year  = {2026},

date = {2026-02-00},

urldate = {2026-02-00},

journal = {Pharmaceutics},

volume = {18},

number = {2},

publisher = {MDPI AG},

abstract = {<jats:p>Skin cancer (SC) is the most prevalent malignancy worldwide, with subtypes varying in aggressiveness: basal cell carcinoma tends to be locally invasive, squamous cell carcinoma has a higher metastatic risk, and melanoma remains the deadliest form. Current treatments such as surgery, radiotherapy, and systemic chemotherapy are associated with aesthetic and functional morbidity, recurrence, and/or systemic toxicity. Although targeted therapies and immunotherapies offer clinical benefits, their high cost and limited accessibility underscore the need for innovative, affordable alternatives. Metal-based compounds (metallopharmaceuticals) are promising anticancer agents due to their ability to induce oxidative stress, modulate redox pathways, and interact with DNA. However, clinical translation has been limited by poor aqueous solubility, rapid degradation, and low skin permeability. This review discusses the most recent preclinical findings on gold, silver, platinum, palladium, ruthenium, vanadium, and copper complexes, mainly in topical and systemic treatments of SC. Advances in chemical and physical enhancers, such as hydrogels and microneedles, and in drug delivery systems, including bacterial nanocellulose membranes and nanoparticles, as well as liposomes and micelles, for enhancing skin permeation and protecting the integrity of metal complexes are also discussed. Additionally, we examine the contribution of photodynamic therapy to SC treatment and the use of mathematical and computational modeling to simulate skin drug transport, predict biodistribution, and support rational nanocarrier design. Altogether, these strategies aim to bridge the gap between physicochemical innovation and clinical applicability, paving the way for more selective, stable, and cost-effective SC treatments.</jats:p>},

keywords = {Área Pré-Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Social inequalities in cancer incidence and mortality in Campinas, Brazil: a decade of population-based registry data (2010-2019)},

author = {Andrea Paula Bruno von Zuben and Carmino Antonio de Souza },

year  = {2026},

date = {2026-01-20},

urldate = {2026-01-20},

journal = {International Journal of Annals Medical and Health Science},

volume = {4},

issue = {1},

pages = {1-2},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Torricelli2026,

title = {Insights from PSMAfore: impact on health-related quality of life},

author = {Caroline Torricelli and Natália Tobar and André Sasse and Elba Etchebehere},

doi = {10.21037/tau-2025-aw-750},

issn = {2223-4691},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Transl Androl Urol},

volume = {15},

number = {1},

pages = {3--3},

publisher = {AME Publishing Company},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Mastrobuono-Cordeiro2026,

title = {Synthesis, structural characterization and biological evaluation of silver(I) complexes with 2-thiouracil and 2,4-dithiouracil},

author = {Francisco Mastrobuono-Cordeiro and Julia H. Bormio Nunes and Gabriele de M. Pereira and Douglas H. Nakahata and Silmara C.L. Frajácomo and Wilton R. Lustri and João Ernesto de Carvalho and Douglas H. Pereira and Ana Lúcia T.G. Ruiz and Raphael E.F. de Paiva and Pedro P. Corbi},

doi = {10.1016/j.ica.2025.122971},

issn = {0020-1693},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Inorganica Chimica Acta},

volume = {590},

publisher = {Elsevier BV},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{deLacerda2026b,

title = {A new palladium(II) complex containing ethylenediamine and 2-thioxo-4-thiazolidinone exhibits high activity against resistant Campylobacter jejuni strains},

author = {Meiry Leandra de Lacerda and Letícia Roberta Martins Costa and Dayanne Maria da Silva Coimbra and Gabriele de Menezes Pereira and Clara Maria Faria Silva and Pedro Paulo Corbi and Daise Aparecida Rossi and Robson José de Oliveira Júnior and Roberta Torres de Melo and Wendell Guerra},

doi = {10.1016/j.ica.2025.122913},

issn = {0020-1693},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Inorganica Chimica Acta},

volume = {589},

publisher = {Elsevier BV},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{Genaro2025b,

title = {Interpretable Artificial Neural Network Models for Predicting Anti-Adalimumab Immune Complex and Serum Drug Level in Crohn’s Disease: A Proof-of-Concept Study},

author = {Livia Moreira Genaro and Juliana Carron and Gustavo Jacob Lourenço and Cristiane Kibune Nagasako and Glaucia Fernanda Soares Rupert Reis and Michel Gardere Camargo and Priscilla de Sene Portel Oliveira and Carmen Silvia Passos Lima and Maria de Lourdes Setsuko Ayrizono and Anibal Tavares de Azevedo and Raquel Franco Leal},

doi = {10.3390/pharmaceutics17121536},

issn = {1999-4923},

year  = {2025},

date = {2025-12-00},

urldate = {2025-12-00},

journal = {Pharmaceutics},

volume = {17},

number = {12},

publisher = {MDPI AG},

abstract = {<jats:p>Background: The development of anti-drug antibodies (ADAs) and resulting immune complexes are key mechanisms behind the secondary loss of response to adalimumab in Crohn’s disease (CD). Despite their clinical importance, routine immunogenicity assays are limited, underscoring the need for alternative predictive approaches. Objective: This study aimed to develop interpretable artificial neural network (ANN) models to predict immune complex formation and estimate serum adalimumab levels using routinely available clinical and laboratory data from CD patients. Methods: A prospective analysis was performed on 58 CD patients on maintenance adalimumab. Immune complexes and serum adalimumab were measured via ELISA and lateral flow assays. ANN and ensemble regression models were trained on demographic, clinical, and inflammatory data, with performance evaluated by five-fold cross-validation. Interpretability was enhanced using Garson’s algorithm and permutation importance. Results: The ANN-based classification model accurately predicted ADA immune complex formation, achieving an accuracy of 77.47% and an area under the curve (AUC) of 82.63%. The main predictive variables included extraintestinal manifestations, perianal disease, disease behavior, and age at diagnosis. For estimating serum adalimumab levels measured by ELISA, the model performed modestly (accuracy 59.89%, AUC 79.72%), incorporating factors such as Montreal classification, perianal disease, C-reactive protein, immunosuppressant use, and disease duration. Conclusions: Interpretable ANN models robustly predict anti-adalimumab immune complexes and, to a lesser extent, serum adalimumab, using clinically available data, including perianal disease. This proof-of-concept study is limited by the relatively small, single-center dataset (n = 58), which may affect model generalizability and increase the risk of overfitting. External validation in larger and multicenter cohorts is required before clinical implementation.</jats:p>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Souza2025,

title = {Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study},

author = {Stephan Souza and Felipe Ribeiro and Ana Brito and Thaís Minekawa and Flávia Lopes and Sumara Matedi and Renata Fockink and Dalton Anjos and Gustavo Gomes and Laura Silva and Mariana Camacho and Allan Santos and Whemberton Araújo and Ana Teixeira and Raul Martins and Adelina Sanches and Nilton Hanaoka and Rafael Tavares and Felipe Villela-Pedras and Felipe Mourato and Caroline Torricelli and Thiago Alves and Marcelo Tavares and Mariana Lima and André Moraes and André Sasse and Paulo Almeida and Elba Etchebehere},

doi = {10.1186/s41824-025-00245-9},

issn = {3005-074X},

year  = {2025},

date = {2025-12-00},

urldate = {2025-12-00},

journal = {EJNMMI Rep.},

volume = {9},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2025b,

title = {Quantification in Clinical Nuclear Medicine: A Language Before a Number},

author = {Celso Dario Ramos},

doi = {10.1097/rlu.0000000000006145},

issn = {1536-0229},

year  = {2025},

date = {2025-10-30},

urldate = {2025-10-30},

journal = {Clinical Nuclear Medicine},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Coelho2025,

title = {Exploring biological properties of sulfa-based copper(II) complexes: in vitro genotoxicity, cytotoxicity (2D and 3D) and mechanistic insights},

author = {Maria Paula M. Coelho and Gabriele de Menezes Pereira and Pedro Paulo Corbi and Douglas H. Nakahata and Valentina Gandin and Chiara Donati and Juliana F. Vecina and Ana Lucia T. G. Ruiz},

doi = {10.1007/s10534-025-00719-0},

issn = {1572-8773},

year  = {2025},

date = {2025-10-00},

urldate = {2025-10-00},

journal = {Biometals},

volume = {38},

number = {5},

pages = {1551--1567},

publisher = {Springer Science and Business Media LLC},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2025,

title = {Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept},

author = {Celso Dario Ramos},

doi = {10.2967/jnumed.125.270245},

issn = {2159-662X},

year  = {2025},

date = {2025-09-00},

urldate = {2025-09-00},

journal = {J Nucl Med},

volume = {66},

number = {9},

pages = {1498--1498},

publisher = {Society of Nuclear Medicine},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025b,

title = {Prognostic impact of low muscularity in metastatic and recurrent head and neck cancer: Insights from C3-based assessments},

author = {Larissa Ariel Oliveira Carrilho and Livia Dias Guerra and Rafaella Caroline de Lellis Moreira and Fabiana Lascala Juliani and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Fabíola Furtuoso Zaperlão and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Moraes Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2025.06.029},

issn = {2405-4577},

year  = {2025},

date = {2025-08-00},

urldate = {2025-08-00},

journal = {Clinical Nutrition ESPEN},

volume = {68},

pages = {767--773},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Nakahata2025,

title = {Pd(II) complexes of 4-(2-aminoethyl)benzenesulfonamide Schiff bases: Structure, DNA binding and antiproliferative activity},

author = {Douglas H. Nakahata and Gabriele de M. Pereira and Marcos A. Ribeiro and Igor S. Oliveira and Josélia C. de Oliveira Moreira and Robson Pontes and João E. de Carvalho and Ana Lucia T.G. Ruiz and Nicholas P. Farrell and Pedro P. Corbi},

doi = {10.1016/j.ica.2025.122659},

issn = {0020-1693},

year  = {2025},

date = {2025-06-00},

urldate = {2025-06-00},

journal = {Inorganica Chimica Acta},

volume = {581},

publisher = {Elsevier BV},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2025,

title = {Evaluation of quality parameters, physicochemical and bioactive properties of licuri oil (Syagrus coronata)},

author = {Gabriel Sthefano Lourenço Pereira and Patrícia Tonon de Souza and Grace Kelly Mizuno Flozino and Rafael Fernandes Almeida and Dhayna Oliveira Sobral and Marcelo Antonio Morgano and Wilton Rogério Lustri and Silmara Cristina Lazarini and Pedro Paulo Corbi and Antonio José de Almeida Meirelles and Guilherme José Maximo and Eduardo Augusto Caldas Batista and Klicia Araujo Sampaio},

doi = {10.1016/j.foodres.2025.116157},

issn = {0963-9969},

year  = {2025},

date = {2025-05-00},

urldate = {2025-05-00},

journal = {Food Research International},

volume = {208},

publisher = {Elsevier BV},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025,

title = {Adipose tissue characteristics as a new prognosis marker of patients with locally advanced head and neck cancer},

author = {Larissa Ariel Oliveira Carrilho and Fabiana Lascala Juliani and Rafaella Caroline de Lellis Moreira and Livia Dias Guerra and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Macedo Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.3389/fnut.2025.1472634},

issn = {2296-861X},

year  = {2025},

date = {2025-03-14},

urldate = {2025-03-14},

journal = {Front. Nutr.},

volume = {12},

publisher = {Frontiers Media SA},

abstract = {<jats:sec><jats:title>Background</jats:title><jats:p>Patients with head and neck cancer (HNC) are at increased risk of malnutrition due to the presence of tumor and treatments. Body composition is a prognostic factor in these patients. However, the relationship between adipose tissue characteristics and survival in HNC is still unclear.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the associations of adiposity, the radiodensity of adipose tissue and muscularity with the prognosis of patients with locally advanced HNC undergoing to chemoradiotherapy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This retrospective study included 132 patients diagnosed with locally advanced HNC. Body composition assessment was performed using computed tomography (CT) images at the level of the third cervical vertebra (C3). The total adipose tissue radiodensity (TATR), the total adipose tissue index (TATI) and skeletal muscle index (SMI) were evaluated. The primary outcome was overall survival (OS).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients in the highest TATI tertile had a lower risk of mortality when compared to those in the lowest tertile, HR: 0.56, 95% confidence Interval (CI): 0.32–0.96; <jats:italic>p</jats:italic> = 0.039. The highest TATR tertile was not associated with death. Patients with greater adiposity had a higher median survival compared to patients with medium and lower TATI (<jats:italic>p</jats:italic> = 0.0193). Individuals with lower TATI had lower energy intake than patients with higher TATI (<jats:italic>p</jats:italic> = 0.03). Additionally, patients with low muscularity had worse OS in the multivariable analysis (HR: 1.77, 95% CI: 1.01–3.07; <jats:italic>p</jats:italic> = 0.044).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In patients with locally advanced HNC, our findings underscore the significance of elevated adiposity, beyond maintained muscularity, as independent protective factors for overall survival. Our study highlights the critical importance of assessing body composition and initiating early nutritional interventions to improve the prognosis of these patients.</jats:p></jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2025b,

title = {Investigating the Antibacterial and Antitumoral Activities of New Copper(II) Complexes with Trifluoromethyluracil Isomers},

author = {Gabriele de Menezes Pereira and Julia Helena Bormio Nunes and Silmara Cristina Lazarini Frajácomo and Wilton Rogério Lustri and Fernando Rodrigues Goulart Bergamini and Josélia Cristina de Oliveira Moreira and Robson Pontes and Ana Lucia T. G. Ruiz and João Ernesto de Carvalho and Wdeson Pereira Barros and Pedro Paulo Corbi},

doi = {10.1002/slct.202405096},

issn = {2365-6549},

year  = {2025},

date = {2025-02-00},

urldate = {2025-02-00},

journal = {ChemistrySelect},

volume = {10},

number = {6},

publisher = {Wiley},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:p>

                    New copper(II) complexes, derived from the isomers 5‐(trifluoromethyl)uracil (

                    <jats:bold>

                      L

                      <jats:sub>1</jats:sub>

                    </jats:bold>

                    ) and 6‐(trifluoromethyl)uracil (

                    <jats:bold>

                      L

                      <jats:sub>2</jats:sub>

                    </jats:bold>

                    ) with 2,2′‐bipyridine (

                    <jats:bold>Bpy</jats:bold>

                    ), [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] and [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy], were synthesized, characterized, and evaluated for their antibacterial and antitumoral properties. Chemical analyses suggest the molecular formula CuC

                    <jats:sub>20</jats:sub>

                    H

                    <jats:sub>12</jats:sub>

                    F

                    <jats:sub>6</jats:sub>

                    N

                    <jats:sub>6</jats:sub>

                    O

                    <jats:sub>4</jats:sub>

                    ·H

                    <jats:sub>2</jats:sub>

                    O for both complexes. Infrared spectroscopic analyses indicate that trifluoromethyluracil isomers coordinate to copper(II) by the oxygen atoms. Structural confirmation of the [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex was obtained by single crystal X‐ray diffraction, where two L

                    <jats:sub>2</jats:sub>

                    molecules coordinate to the copper(II) ion by both oxygen atoms from carbonyl groups. The complexes demonstrated antibacterial activity against Gram‐positive

                    <jats:italic>Staphylococcus aureus</jats:italic>

                    and

                    <jats:italic>Bacillus cereus</jats:italic>

                    , and Gram‐negative

                    <jats:italic>Pseudomonas aeruginosa</jats:italic>

                    and

                    <jats:italic>Escherichia coli</jats:italic>

                    strains. The [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex exhibited the most promising results against

                    <jats:italic>P. aeruginosa</jats:italic>

                    , with a minimum inhibitory concentration (MIC) value of 0.478 mmol L

                    <jats:sup>−1</jats:sup>

                    . The [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex demonstrated antiproliferative effects on U251 and MCF‐7 cells, with GI

                    <jats:sub>50</jats:sub>

                    values (concentration that inhibits 50% of cell growth) of 2.18 ± 1.17 and 16.00 ± 10.07 µmol·L

                    <jats:sup>−1</jats:sup>

                    , whereas the [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex inhibited the growth of FaDu and U251 cells (GI

                    <jats:sub>50</jats:sub>

                    values 4.70 ± 2.69 µmol·L

                    <jats:sup>−1</jats:sup>

                    and 9.06 ± 3.86 µmol·L

                    <jats:sup>−1</jats:sup>

                    , respectively). Neither the precursors nor the copper(II) complexes affected the structure of CT‐DNA at the evaluated concentrations, suggesting that DNA is not the main cellular target of the complexes.

                  </jats:p>},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{deMenezesPereira2025b,

title = {Antibacterial profile and antiproliferative activities over human tumor cells of new silver(I) complexes containing two distinct trifluoromethyl uracil isomers},

author = {Gabriele de Menezes Pereira and Julia H. Bormio Nunes and Vinicius Souza Macedo and Douglas Henrique Pereira and Kaio Eduardo Buglio and Daniele D. Affonso and Ana Lucia T.G. Ruiz and João Ernesto de Carvalho and Silmara Cristina L. Frajácomo and Wilton R. Lustri and Carmen Silvia Passos Lima and Fernando R.G. Bergamini and Alexandre Cuin and Norberto Masciocchi and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2024.112752},

issn = {0162-0134},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Journal of Inorganic Biochemistry},

volume = {262},

publisher = {Elsevier BV},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}

@article{deAraujoFernandes2025,

title = {[99mTc]Technetium and Rhenium Dithiocarbazate Complexes: Chemical Synthesis and Biological Assessment},

author = {André Gustavo de Araujo Fernandes and Alyne Eloise Lafratta and Carolina Portela Luz and Debora Levy and Daniele de Paula Faria and Carlos Alberto Buchpiguel and Ulrich Abram and Victor Marcelo Deflon and Fabio Luiz Navarro Marques},

doi = {10.3390/pharmaceutics17010100},

issn = {1999-4923},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Pharmaceutics},

volume = {17},

number = {1},

publisher = {MDPI AG},

abstract = {<jats:p>Background/Objectives: Dithiocarbazates (DTCs) and their metal complexes have been studied regarding their property as anticancer activities. In this work, using S-benzyl-5-hydroxy-3-methyl-5-phenyl-4,5-dihydro-1H-pirazol-1-carbodithionate (H2bdtc), we prepared [ReO(bdtc)(Hbdtc)] and [[99mTc]TcO(bdtc)(Hbdtc)] complexes for tumor uptake and animal biodistribution studies. Methods: Re complex was prepared by a reaction of H2bdtc and (NBu4)[ReOCl4], the final product was characterized by IR, 1H NMR, CHN, and MS-ESI. 99mTc complex was prepared by the reaction of H2bdtc and [[99mTc]TcO4− and analyzed by planar and HPLC radiochromatography, and the stability was evaluated against amino acids and plasma. Biodistribution was performed in C57B/6 mice with B16F10 and TM1M implanted tumor. Results: Re is asymmetric coordinated by two dithiocarbazate ligands, one with O,N,S chelation, and the other with N,S chelation; [[99mTc]TcO(bdtc)(Hbdtc)] was prepared with a radiochemical yield of around 93%. The radioactive complex is hydrophobic (LogP = 1.03), stable for 6 h in PBS and L-histidine solution; stable for 1 h in plasma, but unstable in the presence of L-cysteine. Ex vivo biodistribution demonstrated that the compound has a fast and persistent (until 2 h) uptake by the spleen (55.46%), and tumor B16F10 and TM1M uptake is lower than 1%. In vivo SPECT/CT imaging confirmed ex vivo biodistribution, except by heterogenous TM1M accumulation but not in the B16-F10 lineage. Conclusions: H2bdtc proved to be an interesting chelator for rhenium or [99mTc]technetium. The right spleen uptake opened the opportunity to deepen the study of the molecule in this tissue and justifies future studies to identify the reason of heterogenous uptake in TM1M tumor uptake.</jats:p>},

keywords = {Área Básica},

pubstate = {published},

tppubtype = {article}

}